Advanced Search

 

Study ID Status Title Patient Level Data
NAIA3002 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NAIA3003 Completed A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks Study Listed on ClinicalStudyDataRequest.com
NAIA3004 Completed A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. Study Listed on ClinicalStudyDataRequest.com
NAIA3005 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. Study Listed on ClinicalStudyDataRequest.com
NAIB1002 Completed A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects Study Listed on ClinicalStudyDataRequest.com
NAIB3001 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Study Listed on ClinicalStudyDataRequest.com
NAIB3002 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NAP109169 Completed An open, randomised, two-period crossover study to investigate the effect of food on the pharmacokinetics of GW273225 administered immediately after food and administered in the fasted state to healthy male and female volunteers.
NEC107110 Terminated An open, repeat dose study to investigate the effect of co-administration of the combined oral contraceptive pill (COC) and GW273225 on the pharmacokinetics of the COC and to investigate the effects of the COC on the pharmacokinetics of GW273225 in healthy female subjects
NKD10020 Completed A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of GW597599, paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subjects affected by social phobia Study Listed on ClinicalStudyDataRequest.com
NKD20006 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
NKE10001 Completed An open-label, repeat-dose, randomized, three-period crossover, parallel-group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.
NKE20001 Completed A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel Group Study of the Efficacy and Safety of a New Chemical Entity When Administered as Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induc ...
NKF100096 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD) Study Listed on ClinicalStudyDataRequest.com
NKF100110 Completed A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
NKG10004 Completed A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and its Effect on the Pharmacokinetics of Midazolam after Once-Daily Repeated Oral Doses in Healthy Subjects
NKG10006 Completed A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE) Study Listed on ClinicalStudyDataRequest.com
NKI110334 Completed A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia Study Listed on ClinicalStudyDataRequest.com
NKO101287 Completed Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous dosing of GW597599 administered with Ondansetron HCL in a female subjects undergoing surgical procedures of high emetogenic risk
NKP102280 Completed A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia. Study Listed on ClinicalStudyDataRequest.com
NKP103401 Completed A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD) Study Listed on ClinicalStudyDataRequest.com
NKP106254 Completed Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss Study Listed on ClinicalStudyDataRequest.com
NKT102245 Completed See Detailed Description
NKT102260 Completed See Detailed Description
NKT102552 Completed A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.